As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating ...
Zacks Investment Research on MSN
Codexis (CDXS) expected to beat earnings estimates: What to know ahead of Q1 release
Codexis (CDXS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for ...
Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Wall Street finally started paying attention to Codexis (NASDAQ: CDXS) in 2017. But as investors are now being reminded, extra attention can bring extra scrutiny. While long-term investors have ...
Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ...
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading enzyme engineering company, today announced the launch of a new mini documentary as part of an ongoing campaign ...
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...
Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies REDWOOD CITY, Calif., ...
As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo ...
Wall Street finally started paying attention to Codexis (CDXS +3.97%) in 2017. But as investors are now being reminded, extra attention can bring extra scrutiny. While long-term investors have enjoyed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results